Full Press Release Details
Strengthens PharmacyChain with Insurance Eligibility & Benefits Verification Capabilities
| Medical insurance eligibility and benefits verification is a core health technology capability necessary for PharmacyChain to gain market adoption | ||
| EBV services offering enabled with preferred pricing being made immediately available to providers, partners and the Wellgistics Pharmacy Network | ||
| EBV market expected to grow from $2.39 billion in 2025 to $3 billion in 2030 according to The Business Research Company 1 |
FL, MARCH 11, 2026 -Wellgistics Health, Inc. (NASDAQ: WGRX) ("Wellgistics"), a health information technology
leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (AI) platform EinsteinRx into
its patented blockchain-enabled smart contracts platform PharmacyChain , today announced that it has secured contractual
rights to preferred pricing for medical insurance eligibility and benefits verification (EBV) that enables PharmacyChain for providers,
partners and pharmacies in order to facilitate its faster adoption into the US healthcare ecosystem. EBV is crucial because it allows
companies that engage in the distribution of medical products and services to know whether a particular product or service is covered
by a patient's insurance carrier and the level of coverage that patient has. This information is paramount to understand provider
reimbursement levels and out-of-pocket costs for patients. Each time a provider requests EBV information, they must pay an out-of-pocket
fee. Wellgistcs is making make preferred pricing on this service available to providers, partners and its Wellgistics Pharmacy Network
immediately through its EinsteinRx AI hub platform in preparation for integration into PharmacyChain later this year.
preferred pricing access to EBV is a major win for Wellgistics," said Prashant Patel, RPh, President & Interim-CEO of Wellgistics.
"It allows to immediately open up a new revenue stream with the exact customers and partners that will eventually utilize our PharmacyChain
smart contracts solution, in addition to reducing our costs for the Company's own pharmacy as we begin the rollout of our GLP-1
and Forzet weight loss offering. The pricing certainty this adds to PharmacyChain allows us to code with confidence as we build
the health technology railroad' smart contracts that will govern the serialization of the drug distribution supply chain,
from manufacturer to patient. We are gaining momentum around our health technology stack, and look forward to making EBV a meaningful
component of our revenue stream beginning in the second quarter of 2026."
market for medical insurance eligibility and benefits verification is expected to grow from $2.39 billion in 2025 to $3 billion in 2030
according to The Business Research Company1. Growth expectations are being attributed to rising US healthcare billing complexity,
increasing insurance claim denial rates, expansion of digital health records usage, growing need for revenue cycle optimization and increased
administrative burden on providers.
interested in speaking with Wellgistics about medical insurance eligibility and benefits verification2 can contact the Company
Wellgistics Health, Inc.
Health (NASDAQ: WGRX) is a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial
intelligence platform EinsteinRx into its patented blockchain-enabled smart contracts platform PharmacyChain to optimize
the prescription drug dispensing journey. Its integrated platform connects 6,500+ pharmacies (the "Wellgistics Pharmacy Network")
and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub
services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment as needed to optimize patient access.
Wellgistics provides end-to-end solutions designed to restore access, transparency, and trust in the U.S. prescription drug market for
independent pharmacies.
more information, visit www.wellgisticshealth.com.
press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements generally relate to future events or the Company's future financial or operating performance and
may include, without limitation, statements regarding the anticipated launch, availability, distribution, commercialization and potential
adoption of Forzet , the expected benefits of the product, the Company's plans to integrate Forzet into its pharmacy network
and telehealth offerings, the development and expansion of the Company's direct-to-consumer initiatives, and the potential growth
of the GLP-1 agonist market. In some cases, forward-looking statements can be identified by terminology such as "may," "will,"
"should," "expects," "plans," "anticipates," "believes," "intends,"
"estimates," "projects," "potential," "continue," or the negative of these terms or other
comparable terminology.
statements are based on current expectations, estimates and assumptions and involve risks and uncertainties that could cause actual results
to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among
other things, risks related to the commercialization and market acceptance of the Company's products and services, the Company's
ability to successfully expand its pharmacy network and telehealth initiatives, regulatory and compliance considerations relating to
medical foods and healthcare products, competition in the healthcare and pharmaceutical distribution markets, changes in market conditions,
and other risks and uncertainties described from time to time in the Company's filings with the U.S. Securities and Exchange Commission.
statements speak only as of the date of this press release, and the Company undertakes no obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise, except as required by law. The Company makes no representation
that Forzet is intended to diagnose, treat, cure, or prevent any disease.
Media & Investor Contact